T1	p 55 84	diabetic nephropathy patients
T2	p 197 221	diabetic nephropathy and
T3	p 320 352	Type 2 diabetic patients ( N.=57
T4	p 392 405	nephropathy (
T5	p 426 439	nephropathy (
T6	p 448 492	. Diabetic nephropathy patients were treated
T7	p 771 775	AGE-
T8	p 841 860	diabetic group with
T9	p 873 877	than
T10	p 898 899	(
T11	p 970 997	group without nephropathy (
T12	p 1034 1065	nephropathy treated either with
T13	p 1350 1405	type 2 diabetes mellitus patients with nephropathy than
T14	p 1438 1482	patients with nephropathy treated with B1+B6
T15	i 6 12	Plasma
T16	i 88 119	thiamine and pyridoxine therapy
T17	i 248 271	thiamine ( vitamin B1 )
T18	i 276 301	pyridoxine ( vitamin B6 )
T19	i 524 535	mg/day ) or
T20	i 731 746	pyrophosphate ,
T21	i 1066 1071	B1+B6
T22	o 6 39	Plasma AGE-peptides and C-peptide
T23	o 163 193	circulatory AGE-peptide levels
T24	o 653 756	glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal
T25	o 809 821	AGE-peptides
T26	o 1196 1219	increase in C-peptide (
T27	o 1274 1304	measured , plasma AGE-peptides
T28	o 1529 1541	AGE-peptides
T29	o 1596 1619	increase in C-peptide .